A new framework for Covid-19 vaccines announced by Food and Drug Administration leaders Tuesday suggests the agency will no longer approve new Covid vaccines for healthy individuals under 65, including babies, without data from new randomized clinical trials showing their benefit.
The plan — described in a commentary in the New England Journal of Medicine, followed by a livestream on YouTube — created confusion among physicians about what it means for young children. While much of the language discussed the need for more data supporting the ongoing use of annual booster shots, it also referred to a lack of evidence for children as young as 6 months, who currently get a two- or three-dose “primary” series of vaccinations.
When asked for clarification, a spokesperson for the department of Health and Human Services did not say how the new approach would affect childhood vaccinations. But STAT was told the framework does not apply to vaccines already on the market, meaning healthy adults and children could still receive existing Covid shots. New trials would only be required for new vaccines or new formulations made to target new viral strains.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
